Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Small Study Finds Fecal Transplant May Benefit Patients with Autism

XTALKS VITALS NEWS

Child

Though the study was small, involving only 18 children with autism, the beneficial effects remained for a minimum of 8 weeks post-treatment.

Share this!

January 24, 2017 | by Sarah Hand, M.Sc.

Researchers at Ohio State University have found that fecal transplants reduced some of the symptoms associated with gastrointestinal distress, as well as behavioral traits associated with autism. Though the study was small, involving only 18 children with autism, the beneficial effects remained for a minimum of 8 weeks post-treatment.

Children with autism often suffer from gastrointestinal problems, which can range from stomach pain to diarrhea. Fecal transplants involve collecting microbe-rich fecal samples from healthy individuals and introducing them to patients with gastrointestinal imbalances. These fecal transplants have been investigated as a potential treatment for numerous conditions, including antibiotic-resistant infections and ulcerative colitis.



“Transplants are working for people with other gastrointestinal problems,” said Ann Gregory, a microbiology graduate student at The Ohio State University, and one of the authors on the study. “And, with autism, gastrointestinal symptoms are often severe, so we thought this could be potentially valuable.”

Previous research has shown that autistic children often have a less-diverse microbiome, which has been attributed to heavy antibiotic use during infanthood. Differences in the microbial makeup of the gut in patients with autism were confirmed in the current study, using samples collected from non-autistic children as a comparison.

Using a scale to rank gastrointestinal symptoms, the researchers found patients’ symptoms were reduced by an average of 82 percent after receiving the fecal transplant. What’s more, parents reported improvements in their children’s behavioural symptoms during the study.

“Following treatment, we found a positive change in GI symptoms and neurological symptoms overall,” said Gregory. According to the researchers, the microbiome of patients with autism was near-identical to their healthy counterparts at the end of the study.

As this was a small, non-blinded observational study, there are limits to how this result can be interpreted. However, a larger clinical trial is in the works to assess whether fecal transplants could be a potential treatment for autism.


Keywords: Autism, Gastrointestinal, Microbiome


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.